Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor01: Dato-DXd in Advanced Solid Tumors
NCT03401385Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer and 11 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with adverse events and 1 more. Started Jan 2018; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)hormone receptor-positive breast cancersmall cell lung cancer (SCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03401385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401385.